Zydus Therapeutics is a clinical stage, specialty-focused biotechnology company focused on developing transformative treatments to transform lives, starting with rare and serious liver diseases.
Committed to Solutions
As a subsidiary of Zydus Lifesciences, we have access to strong research, development and manufacturing capabilities.
- Our research pipeline is fueled by 1,300 researchers who are working with cutting-edge technologies to discover new medicines for tomorrow.
- Our manufacturing network includes over 30 sites with capability from API development through tablet and biologics manufacturing.
Chris is the Chief Operating Officer at Zydus Therapeutics. In this role he oversees all aspects of the company's commercialization strategy and execution.
Prior to Zydus Therapeutics, Chris served as Vice President, Global Strategy at Intercept Pharmaceuticals, where he led strategic planning for an asset in development for NASH. Prior to that, Chris held several business leadership roles at Sanofi, AstraZeneca, Bristol-Myers Squibb and Merck.
In his career Chris has built, evolved and led global and market-level strategic and operational teams to achieve launch success across multiple therapeutic areas and geographies.
Chris received his BSc in Biology from Coventry University in the United Kingdom.
Dr. Parmar is a Clinical Pharmacologist with more than 25 years of experience in drug development, with more than 100 scientific presentations and publications to his credit. Deven is a member of ICH Mll working group - Clinical electronic structured Harmonized Protocol. Prior to Zydus Therapeutics, Deven served as Medical Director and Head of Medical Affairs for Prolong Pharmaceuticals.
Deven is a graduate and post-graduate from Grant Medical College and Sir JJ Group of Hospitals, Mumbai India.